Ascentage Pharma Group International
ASPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 4.45 | 0.01 | -0.07 | -0.14 |
| FCF Yield | -3.18% | 4.04% | -6.40% | -5.60% |
| EV / EBITDA | -27.71 | -13.38 | 27.85 | -14.89 |
| Quality | ||||
| ROIC | -3.07% | -25.47% | 6.78% | -23.93% |
| Gross Margin | 74.26% | 91.06% | 98.17% | 84.37% |
| Cash Conversion Ratio | 0.11 | -0.44 | -2.17 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | 207.34% | 254.64% | 273.62% | 172.56% |
| Free Cash Flow Growth | -292.19% | 163.43% | -0.32% | 8.12% |
| Safety | ||||
| Net Debt / EBITDA | -0.11 | -0.92 | 2.61 | -1.47 |
| Interest Coverage | -19.93 | -8.65 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.52 | 2.13 | 1.41 | 0.77 |
| Cash Conversion Cycle | -237.02 | -490.95 | -339.31 | -243.22 |